AU2004280257A1 - Treatment of diseases involving ErbB2 kinase overexpression - Google Patents

Treatment of diseases involving ErbB2 kinase overexpression Download PDF

Info

Publication number
AU2004280257A1
AU2004280257A1 AU2004280257A AU2004280257A AU2004280257A1 AU 2004280257 A1 AU2004280257 A1 AU 2004280257A1 AU 2004280257 A AU2004280257 A AU 2004280257A AU 2004280257 A AU2004280257 A AU 2004280257A AU 2004280257 A1 AU2004280257 A1 AU 2004280257A1
Authority
AU
Australia
Prior art keywords
cancer
cocoa
erbb2
kinase
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004280257A
Other languages
English (en)
Inventor
Harold H. Schmitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mars Inc
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc filed Critical Mars Inc
Publication of AU2004280257A1 publication Critical patent/AU2004280257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004280257A 2003-10-10 2004-10-08 Treatment of diseases involving ErbB2 kinase overexpression Abandoned AU2004280257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51060403P 2003-10-10 2003-10-10
US60/510,604 2003-10-10
PCT/US2004/033355 WO2005034879A2 (en) 2003-10-10 2004-10-08 Treatment of diseases involving erbb2 kinase overexpression

Publications (1)

Publication Number Publication Date
AU2004280257A1 true AU2004280257A1 (en) 2005-04-21

Family

ID=34435110

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004280257A Abandoned AU2004280257A1 (en) 2003-10-10 2004-10-08 Treatment of diseases involving ErbB2 kinase overexpression

Country Status (9)

Country Link
US (1) US20050245601A1 (enExample)
EP (1) EP1670455A4 (enExample)
JP (1) JP2007508316A (enExample)
CN (1) CN1889944A (enExample)
AU (1) AU2004280257A1 (enExample)
CA (1) CA2541548A1 (enExample)
IL (1) IL174763A0 (enExample)
RU (1) RU2006115615A (enExample)
WO (1) WO2005034879A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006263669B9 (en) * 2005-06-29 2012-12-13 Mars, Incorporated Inducing peripheral blood vessel vasodilation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2004208B1 (en) * 2005-12-23 2017-01-25 Mars, Incorporated Skin protection and improvement
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554645A (en) * 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
CN1159019C (zh) * 1996-04-02 2004-07-28 火星有限公司 可提取物化合物以及其制备方法和用途
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6207842B1 (en) * 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
US6156912A (en) * 1999-04-09 2000-12-05 Mars, Incorporated 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation
US7015338B1 (en) * 1999-04-15 2006-03-21 Mars Incorporated Synthetic methods for preparing procyanidin oligomers

Also Published As

Publication number Publication date
IL174763A0 (en) 2008-04-13
EP1670455A2 (en) 2006-06-21
JP2007508316A (ja) 2007-04-05
WO2005034879A2 (en) 2005-04-21
RU2006115615A (ru) 2007-11-27
EP1670455A4 (en) 2008-10-15
US20050245601A1 (en) 2005-11-03
CN1889944A (zh) 2007-01-03
CA2541548A1 (en) 2005-04-21
WO2005034879A3 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
US20190269715A1 (en) Compositions and method of use of a-type procyanidins
US8568805B2 (en) Cognitive function
CN101516407B (zh) 改善精氨酸酶水平/活性
US20050171029A1 (en) Methods and compositions for treating cancer
US20050245601A1 (en) Treatment of diseases involving ErbB2 kinase overexpression
WO2011108487A1 (ja) 筋萎縮阻害剤
WO2007053641A2 (en) A-type procyanidins and inflammation
CN101228148A (zh) 可用于改进血管健康的热处理可可产品
Kenny et al. Pentameric procyanidins isolated from Theobroma cacao seeds selectively downregulate ErbB2 in human aortic endothelial cells
US20040162338A1 (en) Flavanols and procyanidins promote homeostasis
CN109640978B (zh) 以芹菜素、姜黄素及和厚朴酚为有效成分包含的肺癌预防或治疗用药学组合物
KR20120115963A (ko) 마 추출물을 포함하는 심혈관계 질환의 예방 또는 치료용 조성물
KR102063962B1 (ko) 캄펜을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
US20070004652A1 (en) Treatment of occlusive thrombosis
US20090286869A1 (en) Flavanols and B-Type Procyanidins and Inflammation
WO2007053639A2 (en) A-type procyanidins and cox-2 expression
WO2007053642A1 (en) Flavanols and b-type procyanidins and cox-2 expression

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application